 | ||
Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.
Contents
Griphon dose related efficacy with oral selexipag chest 2015
History
The US FDA granted selexipag Orphan Drug status for PAH. It was approved by the US FDA on 22 December 2015. The expected price for the drug in the US is $160,000 to $170,000 per patient before rebates.
References
Selexipag Wikipedia(Text) CC BY-SA